Fulgent Genetics Inc
For the period ended Jun 30, 2024. Filed Aug 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 2, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Fulgent Stockholders’ Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares (1) · Amount · Additional Paid-In Capital · Accumulated Other ComprehensiveIncome (Loss) · Retained Earnings · Fulgent Stockholders’ Equity · Noncontrolling Interest · Total Equity | ||||||||||
| Balance at December 31, 2023 | 29,653 | $3 | $501,718 | $1,205 | $633,175 | $1,136,101 | $(2,815) | $1,133,286 | ||
| Equity-based compensation | — | — | 11,518 | — | — | 11,518 | — | 11,518 | ||
| Exercise of common stock options | 1 | — | — | — | — | — | — | — | ||
| Restricted stock awards | 315 | — | — | — | — | — | — | — | ||
| Common stock withholding for employee tax obligations | (69) | — | (1,682) | — | — | (1,682) | — | (1,682) | ||
| Repurchase of common stock | (10) | — | (225) | (225) | (225) | |||||
| Other comprehensive loss, net | — | — | — | (2,307) | — | (2,307) | (98) | (2,405) | ||
| Net loss | — | — | — | — | (13,462) | (13,462) | (384) | (13,846) | ||
| Balance at March 31, 2024 | 29,890 | $3 | $511,329 | $(1,102) | $619,713 | $1,129,943 | $(3,297) | $1,126,646 | ||
| Equity-based compensation | — | — | 11,635 | — | — | 11,635 | — | 11,635 | ||
| Restricted stock awards | 212 | — | — | — | — | — | — | — | ||
| Common stock withholding for employee tax obligations | (26) | — | (544) | — | — | (544) | — | (544) | ||
| Repurchase of common stock | — | — | — | — | — | — | — | — | ||
| Common stock issued in a business combination (1) | 186 | — | — | — | — | — | — | — | ||
| Other comprehensive income (loss), net | — | — | — | 225 | — | 225 | (24) | 201 | ||
| Net loss | — | — | — | — | (8,710) | (8,710) | (380) | (9,090) | ||
| Balance at June 30, 2024 | 30,262 | $3 | $522,420 | $(877) | $611,003 | $1,132,549 | $(3,701) | $1,128,848 | ||
(1)185,503 shares of the Company's common stock were issued in May 2024 by the Company upon expiration of hold back provisions in connection with the business combination of Fulgent Pharma Holdings, Inc., or Fulgent Pharma, in 2022.
Condensed Consolidated Statements of Stockholders’ Equity
| Fulgent Stockholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares (1) | Amount | Additional Paid-In Capital | Accumulated Other ComprehensiveIncome (Loss) | Retained Earnings | Fulgent Stockholders’ Equity | Noncontrolling Interest | Total Equity | |
| Balance at December 31, 2022 | 29,438 | $3 | $486,585 | $(20,903) | $801,000 | $1,266,685 | $3,190 | $1,269,875 |
| Equity-based compensation | — | — | 10,265 | — | — | 10,265 | — | 10,265 |
| Restricted stock awards | 280 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (26) | — | (869) | — | — | (869) | — | (869) |
| Other comprehensive income, net | — | — | — | 3,707 | — | 3,707 | 1,790 | 5,497 |
| Net loss | — | — | — | — | (15,340) | (15,340) | (509) | (15,849) |
| Balance at March 31, 2023 | 29,692 | $3 | $495,981 | $(17,196) | $785,660 | $1,264,448 | $4,471 | $1,268,919 |
| Equity-based compensation | — | — | 10,323 | — | — | 10,323 | — | 10,323 |
| Exercise of common stock options | 8 | — | 3 | — | — | 3 | — | 3 |
| Restricted stock awards | 225 | — | — | — | — | — | — | — |
| Common stock withholding for employee tax obligations | (8) | — | (232) | — | — | (232) | — | (232) |
| Other comprehensive loss, net | — | — | — | (3,550) | — | (3,550) | (547) | (4,097) |
| Net loss | — | — | — | — | (11,229) | (11,229) | (361) | (11,590) |
| Balance at June 30, 2023 | 29,917 | $3 | $506,075 | $(20,746) | $774,431 | $1,259,763 | $3,563 | $1,263,326 |
(1)As of June 30, 2023,371,006 shares of the Company's common stock were not issued and were held back by the Company as partial security for the indemnification obligations in connection with the business combination of Fulgent Pharma, in 2022.185,503 shares of the Company’s common stock were issued upon expiration of these hold back provisions in November 2023, and 185,503 shares were issued upon expiration of these hold back provisions in May 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.